Skip to main content

Alector, Inc. (ALEC)

NASDAQ: ALEC · IEX Real-Time Price · USD
21.68 1.85 (9.30%)
Dec 7, 2021 11:32 AM EST - Market open
Market Cap1.76B
Revenue (ttm)197.94M
Net Income (ttm)-32.90M
Shares Out81.28M
EPS (ttm)-0.42
PE Ration/a
Forward PE666.67
Dividendn/a
Ex-Dividend Daten/a
Volume128,403
Open20.31
Previous Close19.83
Day's Range20.31 - 21.68
52-Week Range14.09 - 43.32
Beta1.09
AnalystsStrong Buy
Price Target45.14 (+108.3%)
Earnings DateNov 9, 2021

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that ...

IndustryBiotechnology
IPO DateFeb 7, 2019
CEOArnon Rosenthal
Employees185
Stock ExchangeNASDAQ
Ticker SymbolALEC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Alector stock is "Strong Buy." The 12-month stock price forecast is 45.14, which is an increase of 108.26% from the latest price.

Price Target
$45.14
(108.26% upside)
Analyst Consensus: Strong Buy

News

Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for De...

TAMPA, Fla.--(BUSINESS WIRE)---- $ALEC #AL001--Alzamend Neuro Announces Date for Delivery of Topline Data for Phase 1 First-in-Human Clinical Trial for AL001 for Dementia Related to Alzheimer's

1 week ago - Business Wire

Alector Presents Preclinical Data from AL009 Multi-Siglec Inhibitor Program at the Society for Immunotherapy of Cance...

Preclinical Oncology Program Highlights Alector's Expertise  in Harnessing Components of the Innate Immune System to Impact Disease

3 weeks ago - GlobeNewsWire

Alector (ALEC) Lags Q3 Earnings and Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of -50.00% and -55.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Alector to Present New Data from Multiple Pipeline Programs at 2021 CTAD Conference and SITC Annual Meeting

Company to Host Analyst and Investor Conference Call on November 12 at 4:00 p.m. ET

1 month ago - GlobeNewsWire

Alector (ALEC) Earnings Expected to Grow: Should You Buy?

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Alector Announces Appointment of Elizabeth A. Garofalo, M.D.

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the addition of Elizabet...

2 months ago - GlobeNewsWire

Why Alector Shares Are Diving Today

There has been a major shakeup in the C-suite.

2 months ago - The Motley Fool

Alector Provides Executive Leadership Update

Planned Transitions Announced for Shehnaaz Suliman, M.D., MBA, MPhil, President and Chief Operating Officer and Robert Paul, M.D., Ph.D., Chief Medical Officer

2 months ago - GlobeNewsWire

Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of 0.00% and -26.41%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Alector Reports Second Quarter 2021 Financial Results

Presented twelve-month data from ongoing AL001 open-label Phase 2 study in FTD-GRN at the 2021 Alzheimer's Association International Conference (AAIC)

4 months ago - GlobeNewsWire

Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

Alector Stock Falls After Flashing 12-Month Data From Mid-Stage Trial In Frontotemporal Dementia Patients

Alector Inc (NASDAQ: ALEC) detailed early data from its lead drug, AL001, INFRONT-2 Phase trial at the Alzheimer's Association International Conference (AAIC 2021) Patients with one type of frontotempor...

4 months ago - Benzinga

Alector Presents 12-Month Results from the INFRONT-2 Phase 2 Open-label Clinical Study of AL001 for the Treatment of ...

AL001 Successfully Restored Progranulin to Normal Levels in FTD-GRN Patients

4 months ago - GlobeNewsWire

Alector to Present New Data from Frontotemporal Dementia and Alzheimer's Disease Programs at the 2021 Alzheimer's Ass...

Oral Presentation to Highlight Data from the Ongoing Phase 2 Study of AL001 in FTD-GRN Company to Host Analyst and Investor Conference Call on July 29 at 1:00 p.m. ET

4 months ago - GlobeNewsWire

Alector's (ALEC) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Alector, Inc. (ALEC).

4 months ago - Zacks Investment Research

Why Alector Zoomed 12% Higher Today

The company has yet another fine July trading day thanks to a Citigroup analyst.

5 months ago - The Motley Fool

Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications

Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.

Other symbols:GSK
5 months ago - Zacks Investment Research

Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases

Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ??? for treating various neurodegenerative diseases.

Other symbols:GSK
5 months ago - Zacks Investment Research

Alector (ALEC) Stock Jumps 57.1%: Will It Continue to Soar?

Alector (ALEC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

5 months ago - Zacks Investment Research

Why Alector Blasted Higher Today

It's not every day that a small biotech announces a major collaboration deal with a deep-pocketed pharmaceutical giant.

Other symbols:GSK
5 months ago - The Motley Fool

Don't Miss What Sent These 2 Little-Known Nasdaq Newsmakers Soaring

One of these companies is making big waves.

Other symbols:GSK
5 months ago - The Motley Fool

ALEC Stock: 12 Things to Know About Alector as GSK News Sends It Rocketing Higher

Alector (ALEC) stock is rocketing higher on Friday after the biotechnology company announced a partnership with GlaxoSmithKline (GSK). The post ALEC Stock: 12 Things to Know About Alector as GSK News Se...

Other symbols:GSK
5 months ago - InvestorPlace

Alector Shares Jump On $2.2B Immuno-Neurology Development Pact With GSK

Alector Inc (NASDAQ: ALEC) and GlaxoSmithKline plc (NYSE: GSK) have announced a global collaboration for the development and commercialization of two monoclonal antibodies designed to elevate progranuli...

Other symbols:GSK
5 months ago - Benzinga

Alector and GSK announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal an...

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the d...

5 months ago - GlobeNewsWire